Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-19
2007-06-19
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S210180, C544S236000, C544S230000
Reexamination Certificate
active
10853993
ABSTRACT:
Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
REFERENCES:
patent: 4925846 (1990-05-01), Deacon et al.
patent: 4944790 (1990-07-01), Moser et al.
patent: 5051518 (1991-09-01), Murray et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5744491 (1998-04-01), Boigegrain et al.
patent: 5744493 (1998-04-01), Boigegrain et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6100259 (2000-08-01), Xiang et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6355631 (2002-03-01), Bouchard et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 6642258 (2003-11-01), Bourrie et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2001/0053788 (2001-12-01), Lange et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0019421 (2002-02-01), Biberman et al.
patent: 2002/0035102 (2002-03-01), Achard et al.
patent: 2002/0091114 (2002-07-01), Plot-Grosjean et al.
patent: 2002/0119972 (2002-08-01), Lefteris et al.
patent: 2002/0128302 (2002-09-01), Maruani et al.
patent: 2002/0188007 (2002-12-01), Barth et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0087933 (2003-05-01), Blanchard et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2003/0139386 (2003-07-01), Cole et al.
patent: 2003/0199536 (2003-10-01), Thomas et al.
patent: 2004/0072833 (2004-04-01), Nakai et al.
patent: 2004/0077650 (2004-04-01), Dow
patent: 2004/0092520 (2004-05-01), Griffith
patent: 2004/0122074 (2004-06-01), Dow et al.
patent: 2004/0157838 (2004-08-01), Griffith
patent: 2004/0157839 (2004-08-01), Griffith
patent: 2004/0214837 (2004-10-01), Griffith et al.
patent: 2004/0214838 (2004-10-01), Carpino et al.
patent: 2004/0214855 (2004-10-01), Carpino et al.
patent: 2004/0214856 (2004-10-01), Carpino et al.
patent: 2004/0235926 (2004-11-01), Sakya
patent: 2387138 (2001-04-01), None
patent: 1354884 (2003-10-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 00/15609 (2000-05-01), None
patent: WO 01/029007 (2001-04-01), None
patent: WO 01/032629 (2001-05-01), None
patent: WO 01/032663 (2001-05-01), None
patent: WO 01/85092 (2001-11-01), None
patent: WO02053565 (2002-07-01), None
patent: WO 02/076949 (2002-10-01), None
patent: WO 03/006007 (2003-01-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/018060 (2003-03-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/020314 (2003-03-01), None
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 03/027069 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/075660 (2003-09-01), None
patent: WO 03/077847 (2003-09-01), None
patent: WO 03/078413 (2003-09-01), None
patent: WO 03/082190 (2003-10-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 03/082256 (2003-10-01), None
patent: WO 03/082833 (2003-10-01), None
patent: WO 03/084943 (2003-10-01), None
patent: WO 03/086288 (2003-10-01), None
patent: WO 03/087037 (2003-10-01), None
patent: WO03095455 (2003-11-01), None
patent: WO 2004/012617 (2004-02-01), None
Sener et al. Journal of Heterocyclic Chemistry 2002, 39(5), 869-875.
Tzavara, E.T., et al., “The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions,”J. Pharmacol, 138, 544-553 (2003).
Racz, I., et al., “A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking,”J. Neurosci, 23(6), 2453-2458 (2003).
Croci, T., et al., “Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents,”Brit J Pharmacol, 140, 115-122 (2003).
DaSilva, G.E., et al., “Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats,”Neurosci Let, 349, 49-52 (2003).
Wang, L., et al., “Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice,”PNAS, 100(3), 1393-1398 (2003).
Ruiu, S., et al., “Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor,”J Pharmacol Exp Therap, 306, 363-370 (2003).
Howlett, A.C., et al., “International Union of Pharmacology. XXVII. Classification of Cannibinoid Receptors,”Pharmacol Rev, 54, 161-202 (2002).
Gomez, R., et al., “A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding,”J. Neurosci, 22(21), 9612-9617 (2002).
Wiley, J.L., et al., “Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation,”J Pharmacol Exp Therap, 296(3), 1013-1022 (2001).
Lellemand, F., et al., “Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration,”Alcohol Clin Exp Res, 25(9), 1317-1323 (2001).
Pertwee, R.G., “Cannabinoids and the Gastronintestinal Tract,”Gut, 48, 859-867 (2001).
Pertwee, R.G., “Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development,”Exp. Opin. Invest. Drugs, 9(7), 1573-1571 (2001).
Hungund, B.L and B.S. Basavarajappa, “Are Anadamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence,”Alcohol&Alcoholism. 35(2) 126-133, (2000).
Freedland, C.S., et al., “Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding,”Pharmacol Biochem Behav, 67, 265-270 (2000).
Lan, R., et al., “Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists”J. Med. Che.m, 42, 769-776 (1999).
Pertwee, R.G., “Pharmacology of Cannabinoid Receptor Ligands”Curr Med Chem, 6, 635-664 (1999).
Basavarajappa, B.S., et al., “Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane,”Brain Res, 793, 212-218 (1998).
Thomas, B.F., et al., “Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists,”J Pharmacol Exp Therap, 285, 285-292 (1998).
Colombo, G., et al., “Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716,”Life Sci., 63, PL113-PL117 (1998).
Simiand, J., et al., “SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmose,”Behav. Pharmacol., 9, 179-181 (1998).
Chaperon, F., et al., “Involvement of Central Cannabinoid (CB1) Receptors in Establishment of Place Conditioning in Rats,”Psychopharmacology, 135, 324-332 (1998).
Arnone, M., et al., “Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors,”Psychopharmacol, 132, 104-106 (1997).
Savontaus, E., et al., “Anti-Obesity Effect of MPV-1743 A III, a Novel Imidazoline Derivative, in Gentic Obesity,”Eur J Pharmacol, 328, 207-215 (1997).
Sanudo-Pena, M.C., et al., “Endogenous Cannabinoids as an Aversive or Counter-rewarding System in the Rat,”Neurosci Let.223, 125-128 (1997).
Gifford, A.N., et al., &#x
Carpino Philip A.
Sakya Subas M.
Lappin Julie M.
McKane Joseph K.
Nolan Jason M.
Pfizer Inc.
LandOfFree
Cannabinoid receptor ligands and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cannabinoid receptor ligands and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor ligands and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3874024